Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330
Cancer-fighting T-cell therapy effectiveness depends more on having enough immune cells than on cancer cell target density.
A statistical reanalysis of published AMG 330 (CD33 T-cell engager) data in AML shows that effector-to-target ratio explains lytic activity far better than CD33 density (~10x more variance), fundamentally challenging the conventional target density-first paradigm for TCE development. This effector-context framework has implications for TCE dose design, trial stratification, and combination strategies with effector-enhancing agents.
What the study was
- Study design
- Quantitative reanalysis of published data
- Population
- Reanalysis of AMG 330 published data: 11 AML cell lines + 38 primary AML samples + clinical data
- Sample size
- 38
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Investigational New Drugs
Why it surfaced
Biologically insightful reanalysis challenging the dominant CD33 paradigm for T-cell engagers; statistical reanalysis of aggregate published data limits causal inference; single-author single-institution.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.